Multiple pathways of type 1 interferon production in lupus: the case for amlexanox by Todd, Ian et al.
For Peer Review
Multiple pathways of type 1 interferon production in lupus: 
the case for amlexanox.
Journal: Rheumatology
Manuscript ID RHE-20-0856.R1
Manuscript Type: Letter to the Editor (Other)
Date Submitted by the 
Author: n/a
Complete List of Authors: Todd, Ian; University of Nottingham, School of Life Sciences
Thomas, Rhema; University of Nottingham, School of Life Sciences
Watt, Baltina; University of Nottingham, School of Life Sciences
Sutherland, Lissa; University of Nottingham, School of Life Sciences
Afriyie-Asante, Afrakoma; University of Nottingham, School of Life 
Sciences
Deb, Bishnu; University of Nottingham, School of Life Sciences
Joseph, Blessy; University of Nottingham, School of Life Sciences
Tighe, Paddy; University of Nottingham, School of Life Sciences
Lanyon, Peter; Nottingham University Hospitals NHS Trust, Queens 
Medical Centre
Fairclough, Lucy; University of Nottingham, School of Life Sciences
Keywords<br>Please select a 
minimum FIVE keywords from 
the list provided. These 
keywords will be used to 
select reviewers for this 
manuscript.  The keywords in 
the main text of your paper 
do not need to match these 
words.:
Systematic lupus erythematosus and autoimmunity < RHEUMATIC 
DISEASES, Cytokines and inflammatory mediators < BASIC & CLINICAL 
SCIENCES, Inflammation < BASIC & CLINICAL SCIENCES, 





Letter to the Editor
Multiple pathways of type 1 interferon production in lupus: the case for 
amlexanox.
Ian Todd1,3, Rhema E. Thomas1, Baltina D. Watt1, Lissa Sutherland1, 
Afrakoma Afriyie-Asante1, Bishnu Deb1, Blessy Joseph1, Patrick J. Tighe1,3, 
Peter Lanyon2,3, and Lucy C. Fairclough1,3
1School of Life Sciences, The University of Nottingham, UK; 2Department of 
Rheumatology, Nottingham University Hospitals NHS Trust, Nottingham, UK; 
3Nottingham Biomedical Research Centre (Musculoskeletal), Nottingham 
University Hospitals NHS Trust, Nottingham, UK.
Correspondence to: Lucy C. Fairclough, School of Life Sciences, The 
University of Nottingham,  Life Sciences Building, University Park, 
Nottingham, NG7 2RD, UK.
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production and may be therapeutically useful in lupus.































































Sir,   Substantial evidence implicates type-1 interferons (IFN-1s) in the pathophysiology of 
systemic lupus erythematosus (SLE, lupus), and this has led to the development of several 
therapeutic strategies for lupus that target the IFN-1 pathways [1].  In particular, it has 
recently been reported that the therapeutic monoclonal antibody, anifrolumab, showed 
efficacy in meeting its primary endpoint in a phase III clinical trial in active lupus [2].  
Anifrolumab targets the IFN-1 receptor and thereby inhibits the activity of all species of IFN-
1 (,  and ).  Overall, anifrolumab has shown greater promise in lupus than the therapeutic 
monoclonal antibodies that directly target IFN- only (i.e. sifalimumab, rontalizumab) [1].  
This is not surprising, as although many studies have concentrated on the role of IFN- 
derived from plasmacytoid dendritic cells in lupus, it is now apparent that IFN- and IFN- 
are also important in the pathophysiology [3].  With regard to the signalling pathways that are 
triggered in lupus to generate IFN-1 production, emphasis has been placed on the role of the 
DNA sensor TLR9 [4].  However, there is increasing evidence for the involvement of the 
RNA sensor TLR3, RNA sensors such as RIG-1/MDA-5 that stimulate MAVS, and the DNA 
sensors such as cGAS that stimulate STING [4-6]: all of these three pathways act via the 
signalling molecule TBK-1.  Indeed, the type 1 IFN gene signature in peripheral blood 
mononuclear cells of childhood-onset lupus patients can be down-regulated by the TBK-1 
inhibitor BX795 [5].  These and other findings have raised the potential of TBK-1 inhibitors 
as therapeutic agents for lupus [5].   
Amlexanox is used for the topical treatment of aphthous ulcers and has been 
used to a limited degree in allergic asthma. We previously highlighted amlexanox from 
screening 1300 drugs for inhibitory effects on inflammatory signalling pathways [7] and it 
has been shown that amlexanox inhibits the IB kinases TBK-1 and IKK [8].  Based on its 
inhibition of TBK-1 and IKK, amlexanox was recently used systemically in a randomized, 
double-blind, placebo-controlled clinical study in obese patients with type II diabetes and 
non-alcoholic fatty liver disease; it was shown to improve glucose control in a subset of 
patients with an inflammatory profile [9].  Only low-grade adverse side-effects were seen 
during the study. Importantly, therefore, this study demonstrated the clinical efficacy and 
safety of amlexanox when used systemically in patients [9].  
Numerous subsequent studies in vitro and in animal models have demonstrated the 
effectiveness of amlexanox as a TBK-1 inhibitor (e.g. [10]) in a variety of pathological 
settings although, to our knowledge, no studies of amlexanox in relation to lupus have been 
reported to date. However, the potential of amlexanox in lupus is strongly supported by all of 































































these other studies.  It is important, therefore, to be clear that amlexanox inhibits all three of 
the pathways involving TBK-1 that may contribute to the production of IFN-1s in lupus.  
(Most other studies have examined the inhibitory effects of amlexanox on just one or two of 
these pathways: e.g. Raicevic et al. demonstrated that amlexanox inhibits IFN- production 
by mesenchymal stem cells stimulated via the RIG-1/MDA-5 pathway [10].)  
In this regard, we now present evidence that amlexanox downregulates all three 
pathways of TBK-1 activation involving TLR-3, RIG-1/MDA-5/MAVS or cGAS/STING in 
the same cell type.  For this we employed the lung epithelial carcinoma A549-DualTM 
reporter cell line (Invivogen) that expresses Lucia luciferase under the control of IFN-
stimulated response elements.  Thus, induction of luciferase expression acts as a surrogate for 
IFN-1 production and is detected by the action of luciferase on the QUANTI-LucTM detection 
reagent (Invivogen).  The cells were cultured for 16h at 5x104/well in 96-well plates either 
without ligands, or with one of the following: 50g/mL Poly I:C (TLR-3 ligand), 0.1g/mL 
3p-hpRNA plus Lyovec (RIG-1/MDA-5 ligand), or 50g/mL 2’3’cGAMP (STING ligand) 
(all from Invivogen).  The cells were cultured with or without 1M amlexanox (Tocris 
Bioscience).  All the cultures contained dimethyl sulphoxide (1%) as a control as this was the 
solvent for amlexanox.  After 16h, 20l aliquots of the culture supernatants were added to 
50l aliquots of QUANTI-LucTM and the luminescence generated was immediately 
measured.
The results shown in figure 1 for three to six independent experiments are expressed 
as ratios of the luminescence values of supernatants from stimulated cells divided by the 
luminescence values of supernatants from cells cultured without ligands or amlexanox.  
These results show that amlexanox significantly inhibited the stimulation of the A549-DualTM 
cells by all three ligands/pathways.  Amlexanox did not induce death of the cells as 
determined by trypan blue exclusion: cell death was only 2-3% on average following culture 
without or with amlexanox (P=0.4).
Amlexanox did not affect the viability of the cells (data not shown). 
These findings of the effects of amlexanox using the A549-DualTM reporter cell line 
should be confirmed in experiments with human peripheral blood mononuclear cells 
(PBMCs), using synthetic ligands or sera from SLE patients to stimulate IFN-1 production.  
Although these experiments are beyond the scope of this letter, we have preliminary data 
showing that amlexanox inhibits IFN- production by Poly I:C-stimulated PBMCs (data not 
shown).   However, our current data does show Our data therefore shows that amlexanox 































































inhibits all three pathways leading to TBK-1 activation and type 1 IFN production in 
response to particular forms of DNA or RNA ligands.  We propose that this finding, together 
with the previous demonstration of the efficacy and safety of amlexanox administered 
systemically in a clinical trial in type II diabetes and non-alchoholic fatty liver disease [9], 
provides support for amlexanox to be considered for trials as a novel therapeutic agent in 
lupus. 
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Figure legend
FIG 1.  Amlexanox suppresses the activation of multiple signalling pathways involving 
TBK-1.  A549-DualTM cells were cultured for 16h with the indicated ligands (50g/mL Poly 
I:C, 0.1g/mL 3p-hpRNA plus Lyovec, or 50g/mL 2’3’cGAMP), and with or without 1M 
amlexanox.  The culture supernatants were then tested for secreted luciferase by addition to 
QUANTI-LucTM detection reagent.  The results are presented as luminescence ratios of 
luciferase activity of ligand-stimulated cultures (without or with amlexanox) divided by the 
luciferase activity of non-stimulated cultures.  Paired t-test was used to compare the readings 
in the absence or presence of amlexanox (p<0.05 considered significant). 































































FIG 1.  A549-DualTM cells were cultured for 16h with the indicated ligands (50g/mL Poly I:C, 0.1g/mL 
3p-hpRNA plus Lyovec, or 50g/mL 2’3’cGAMP), and with or without 1M amlexanox.  The culture 
supernatants were then tested for secreted luciferase by addition to QUANTI-LucTM detection reagent.  The 
results are presented as luminescence ratios of luciferase activity of ligand-stimulated cultures (without or 
with amlexanox) divided by the luciferase activity of non-stimulated cultures.  Paired t-test was used to 
compare the readings in the absence or presence of amlexanox (p<0.05 considered significant). 
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